文献速递胃肠动力与功能性疾病消化内镜

经口内镜下肌切开术患者阿片类药物使用的患病率及影响

Prevalence and impact of opioid use in patients undergoing peroral endoscopic myotomy.
PubMed 文献 · Gastrointest Endosc · 2022-12-09

本研究纳入2017年4月至2021年9月因III型贲门失弛缓症、食管胃交界处流出道梗阻、弥漫性食管痉挛或高收缩食管接受经口内镜下肌切开术且有至少6个月随访的连续患者。89例患者中18例(20%)每日使用阿片类药物,阿片类药物使用组与非使用组术后临床应答及胃食管反流病频率相似,但阿片类药物组烧心更频繁(82.4% vs 38.6%,P = .002)。

要点

  • 89例接受经口内镜下肌切开术的患者中,20%每日使用阿片类药物。
  • 阿片类药物使用组与非使用组术后临床应答及胃食管反流病频率相似。
  • 阿片类药物组烧心更频繁(82.4% vs 38.6%,P = .002)。

核心结论

  • 在这项纳入89例因III型贲门失弛缓症、食管胃交界处流出道梗阻、弥漫性食管痉挛或高收缩食管接受经口内镜下肌切开术的单中心研究中,20%的患者每日使用阿片类药物;阿片类药物使用组与非使用组对经口内镜下肌切开术的应答及术后胃食管反流病相似。

研究设计与样本

  • 单中心研究,纳入2017年4月至2021年9月因III型贲门失弛缓症、食管胃交界处流出道梗阻、弥漫性食管痉挛或高收缩食管接受经口内镜下肌切开术且随访至少6个月的连续患者。
  • 共126例患者接受经口内镜下肌切开术,其中89例有至少6个月随访。
  • 基线评估包括食管胃十二指肠镜、食管高分辨率测压和食管胃交界处功能性腔阻抗平面测量。
  • 在基线和经口内镜下肌切开术后6至12个月随访时计算Eckardt评分。
  • 临床应答定义为Eckardt评分≤3、食管胃交界处扩张性指数>2.8 mm2/mm Hg、食管胃交界处最大直径>14 mm及整合松弛压<15 mm Hg。

主要发现

  • 89例患者中18例(20%)每日使用阿片类药物。
  • 阿片类药物使用组与非使用组在基线人口学特征、功能性腔阻抗平面测量指标、整合松弛压、动力障碍分布及经口内镜下肌切开术特征方面相似。
  • 经口内镜下肌切开术后6至12个月,阿片类药物使用组与非使用组的临床应答及胃食管反流病、食管炎和质子泵抑制剂使用频率相似。
  • 阿片类药物组烧心更频繁(82.4% vs 38.6%,P = .002)。

关键数值与推荐

  • 临床应答定义为Eckardt评分≤3、食管胃交界处扩张性指数>2.8 mm2/mm Hg、食管胃交界处最大直径>14 mm及整合松弛压<15 mm Hg。
  • 每日阿片类药物使用定义为基线高分辨率测压前评估的阿片类药物使用。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Chronic narcotic use may cause opioid-induced esophageal dysfunction and associated type III achalasia, hypercontractile esophagus (HE), diffuse esophageal spasm (DES), and esophagogastric junction outflow obstruction (EGJOO). The frequency of opioid use and its impact on peroral endoscopic myotomy (POEM) in these patients is unknown. METHODS: Consecutive patients between April 2017 and September 2021 who underwent POEM for type III achalasia, EGJOO, DES, or HE with ≥6 months follow-up were identified. Baseline evaluation was done with EGD, esophageal high-resolution manometry (HRM), and functional lumen impedance planimetry (FLIP) of the esophagogastric junction (EGJ). Eckardt scores (ESs) were calculated at baseline and follow-up at 6 to 12 months after POEM for opioid users and nonusers. Clinical response was defined as ES ≤3, EGJ distensibility index >2.8 mm2/mm Hg, maximum EGJ diameter >14 mm, and integrated relaxation pressure (IRP) <15 mm Hg. Opioid use before baseline HRM was assessed. RESULTS: One hundred twenty-six patients underwent POEM, and 89 had ≥6 months of follow-up. Daily opioid use was present in 18 of 89 patients (20%). Baseline demographics, FLIP metrics, IRP, distribution of motility disorders, and POEM characteristics were similar between both groups. At 6 to 12 months after POEM, clinical response and frequency of GERD, esophagitis, and proton pump inhibitor use were similar between opioid users and nonusers. Heartburn was more frequent in the opioid group (82.4% vs 38.6%, P = .002). CONCLUSIONS: In this single-center study of 89 patients with type III achalasia, EGJOO, DES, or HE treated with POEM, daily opioid use was present in 20%. Response to POEM and post-POEM GERD were similar between opioid users and nonusers. (Clinical trial registration number: NCT02770859.).

来源:Gastrointest Endosc,查看原文。版权归原作者所有。

引用

  1. Jacobs CC, Al-Haddad M, Stainko S, et al. Prevalence and impact of opioid use in patients undergoing peroral endoscopic myotomy. Gastrointest Endosc. 2022. PMID: 36509112. doi:10.1016/j.gie.2022.12.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。